Paper38492132
Prophylaxis of hepatic encephalopathy: current and future drug targets.
Maharshi S and 1 other. Hepatol Int, 2024. Cited by 12 papers, by iCite.
Cite this record
ConductScience Library. Prophylaxis of hepatic encephalopathy: current and future drug targets. Papers, record 38492132. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38492132
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hepatic Encephalopathy | Major topic |
| Lactulose | Major topic |
| Rifaximin | Major topic |
| Humans | |
| Probiotics | |
| Gastrointestinal Agents | |
| Fecal Microbiota Transplantation | |
| Liver Transplantation | |
| Secondary Prevention | |
| Amino Acids, Branched-Chain | |
| Primary Prevention | |
| Dipeptides |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT07273734 | UDCA to Prevent Post-TIPS Hepatic Encephalopathy | Results |
Source ClinicalTrials.gov
References96
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 14730033 | TIPS-related hepatic encephalopathy: management options with novel endovascular techniques. | Radiographics | 2004 | https://conductscience.org/library/papers/14730033 | PubMed |
| 2 | 33768619 | Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double-blind controlled trial. | J Hepatobiliary Pancreat Sci | 2021 | https://conductscience.org/library/papers/33768619 | PubMed |
| 3 | 18691193 | Probiotic yogurt for the treatment of minimal hepatic encephalopathy. | Am J Gastroenterol | 2008 | https://conductscience.org/library/papers/18691193 | PubMed |
| 4 | 23401201 | Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. | Hepatology | 2013 | https://conductscience.org/library/papers/23401201 | PubMed |
| 5 | 30706425 | L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses. | Drugs | 2019 | https://conductscience.org/library/papers/30706425 | PubMed |
| 6 | 34629016 | Budget impact of optimizing rifaximin-α use for the prevention of recurrent hepatic encephalopathy in The Netherlands. | J Med Econ | 2021 | https://conductscience.org/library/papers/34629016 | PubMed |
| 7 | 23216382 | Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. | J Gastroenterol Hepatol | 2013 | https://conductscience.org/library/papers/23216382 | PubMed |
| 8 | 34169435 | Hepatic Encephalopathy-Related Hospitalizations in Cirrhosis: Transition of Care and Closing the Revolving Door. | Dig Dis Sci | 2022 | https://conductscience.org/library/papers/34169435 | PubMed |
| 9 | 28316761 | Polyethylene Glycol and Lactulose versus Lactulose Alone in the Treatment of Hepatic Encephalopathy in Patients with Cirrhosis: A Non-Inferiority Randomized Controlled Trial. | Middle East J Dig Dis | 2017 | https://conductscience.org/library/papers/28316761 | PubMed |
| 10 | 21310833 | Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. | Am J Clin Nutr | 2011 | https://conductscience.org/library/papers/21310833 | PubMed |
| 11 | 35266571 | Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial. | Hepatology | 2022 | https://conductscience.org/library/papers/35266571 | PubMed |
| 12 | 23425082 | Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy. | J Gastroenterol Hepatol | 2013 | https://conductscience.org/library/papers/23425082 | PubMed |
| 13 | 23972578 | Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis. | Clin Ther | 2013 | https://conductscience.org/library/papers/23972578 | PubMed |
| 14 | 17245628 | Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. | Dig Dis Sci | 2007 | https://conductscience.org/library/papers/17245628 | PubMed |
| 15 | 21057793 | Management of transjugular intrahepatic portosystemic shunt (TIPS)-associated refractory hepatic encephalopathy by shunt reduction using the parallel technique: outcomes of a retrospective case series. | Cardiovasc Intervent Radiol | 2011 | https://conductscience.org/library/papers/21057793 | PubMed |
| 16 | 29624860 | Hepatic encephalopathy: Diagnosis and management. | Liver Int | 2018 | https://conductscience.org/library/papers/29624860 | PubMed |
| 17 | 23565181 | Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. | PLoS One | 2013 | https://conductscience.org/library/papers/23565181 | PubMed |
| 18 | 22832139 | Efficacy of balloon-occluded retrograde transvenous obliteration of large spontaneous lienorenal shunt in patients with severe recurrent hepatic encephalopathy with foam sclerotherapy: initial experience. | J Vasc Interv Radiol | 2012 | https://conductscience.org/library/papers/22832139 | PubMed |
| 19 | 11495040 | Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. | J Hepatol | 2001 | https://conductscience.org/library/papers/11495040 | PubMed |
| 20 | 17312051 | Endovascular shunt reduction in the management of transjugular portosystemic shunt-induced hepatic encephalopathy: preliminary experience with reduction stents and stent-grafts. | AJR Am J Roentgenol | 2007 | https://conductscience.org/library/papers/17312051 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42589578 | XGBoost-SHAP Interpretable Modeling Identifies and Validates an Eight-Gene Biomarker for Hepatic Encephalopathy Risk Prediction in Cirrhosis. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42589578 | PubMed |
| 42137345 | Serum metabolomics identifies GPC depletion in hepatic encephalopathy and its therapeutic potential for cognitive impairment. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42137345 | PubMed |
| 42003914 | Amino Acid Metabolism in Chronic Liver Disease: from Pathogenic Driver to Therapeutic Target. | Int J Biol Sci | 2026 | https://conductscience.org/library/papers/42003914 | PubMed |
| 41904644 | The role of systemic inflammation in hepatic encephalopathy: advances in inflammatory mechanisms, prevention and treatment research. | Ann Med | 2026 | https://conductscience.org/library/papers/41904644 | PubMed |
| 41331614 | Advances in capsule-based fecal microbiota transplantation: clinical applications and innovations. | J Transl Med | 2025 | https://conductscience.org/library/papers/41331614 | PubMed |
| 41272855 | Comparison of efficacy of rifaximin, probiotics and L-ornithine L-aspartate in overt hepatic encephalopathy: a randomized, phase IV, lactulose controlled clinical trial. | Trials | 2025 | https://conductscience.org/library/papers/41272855 | PubMed |
| 40309228 | Management of hepatic encephalopathy following transjugular intrahepatic portosystemic shunts: Current strategies and future directions. | World J Gastroenterol | 2025 | https://conductscience.org/library/papers/40309228 | PubMed |
| 40177203 | Smartphone-based Stroop Test, EncephalApp: What is the optimal cutoff for diagnosing minimal hepatic encephalopathy? | World J Hepatol | 2025 | https://conductscience.org/library/papers/40177203 | PubMed |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| URSODIOL | CHEMBL1551 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1551 | ChEMBL |
| LACTULOSE | CHEMBL296306 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL296306 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38492132
GET https://conductscience.org/api/papers/v1/38492132/references?page=2